Menopause Emerging Research and Trials to Watch

NK3 Receptor Antagonists: A Non-Hormonal Breakthrough

The approval of fezolinetant (Veozah) by the FDA in May 2023 marked the first new mechanism for vasomotor symptoms (VMS) in decades. This drug blocks neurokinin 3 (NK3) receptors in the hypothalamic KNDy neurons that become hyperactive when estrogen declines. The result is a direct reduction in the thermoregulatory dysfunction that triggers hot flashes.

In the SKYLIGHT 1 trial (N=501), fezolinetant 45 mg daily reduced moderate-to-severe VMS frequency by approximately 60% at week 12 compared to a 36% reduction with placebo 1. SKYLIGHT 2 (N=500) confirmed these results with statistically significant reductions in both frequency and severity scores at weeks 4 and 12 2. The 52-week SKYLIGHT 4 extension demonstrated durable efficacy without tachyphylaxis, with the most common adverse event being hepatic transaminase elevation in approximately 2% of participants 3.

The clinical significance is clear for women who cannot or prefer not to use hormone therapy. Breast cancer survivors on aromatase inhibitors, women with a history of venous thromboembolism, and patients with hormone-receptor-positive malignancies now have an evidence-based alternative. Liver function monitoring is required at baseline, 3 months, 6 months, and 9 months during treatment.

Elinzanetant: The Dual-Receptor Approach

Elinzanetant differs from fezolinetant by antagonizing both NK1 and NK3 receptors. This dual mechanism may offer an advantage: NK1 receptor blockade is associated with anxiolytic and sleep-promoting effects independent of VMS control.

The OASIS 1 trial (N=399) showed that elinzanetant 120 mg daily reduced weekly VMS frequency by 6.4 events more than placebo at week 12 (P<0.001) 4. OASIS 2 (N=400) replicated these findings and reported significant improvement in menopause-related sleep disturbance as measured by the PROMIS Sleep Disturbance scale 5. The OASIS 3 long-term safety extension through 52 weeks did not reveal hepatotoxicity signals comparable to fezolinetant, though head-to-head comparisons have not been conducted.

Bayer submitted a New Drug Application to the FDA in 2024. If approved, clinicians will have two distinct non-hormonal neurokinin-targeted options, allowing selection based on whether sleep disruption or pure VMS reduction is the primary treatment goal.

Estetrol: A "Native" Estrogen With a Different Risk Profile

Estetrol (E4) is a natural estrogen produced by the fetal liver during pregnancy. Unlike ethinyl estradiol or 17-beta estradiol, E4 acts as a full agonist on nuclear estrogen receptor alpha but has minimal activity on membrane-bound estrogen receptors in vascular and hepatic tissue. This selectivity may translate into lower thrombotic and hepatic risk.

The phase III E4 Comfort trial (N=707) evaluated oral E4 15 mg daily for VMS in postmenopausal women. At week 12, E4 reduced moderate-to-severe hot flash frequency by 78.3% compared to 47.5% for placebo. The reduction persisted through week 52 6. Coagulation biomarker substudies showed that E4 did not significantly increase thrombin generation or sex hormone-binding globulin to the degree observed with conjugated equine estrogens 7.

Dr. Jean-Michel Foidart, principal investigator at the University of Liege, stated: "Estetrol has a unique pharmacological profile among estrogens. Its selective nuclear pathway activity spares the vascular endothelium and liver from the prothrombotic stimulation seen with other oral estrogens" 6.

Ongoing studies are evaluating E4 combined with drospirenone for both VMS relief and endometrial protection. If phase III endometrial safety data confirm the combination's viability, E4-based HRT could offer oral estrogen therapy with a safety margin closer to transdermal estradiol.

The KEEPS Trial: 16 Years of Follow-Up

The Kronos Early Estrogen Prevention Study (KEEPS) was designed to test whether early initiation of hormone therapy (within 3 years of menopause) prevented atherosclerosis. The original 4-year results published in 2014 showed that neither oral conjugated equine estrogens (o-CEE 0.45 mg) nor transdermal estradiol (t-E2 50 mcg) significantly changed carotid intima-media thickness compared to placebo 8.

The 16-year follow-up, presented at the 2024 North American Menopause Society (NAMS) annual meeting, extended these observations. Coronary artery calcium (CAC) scores did not differ significantly between the treatment and placebo groups, confirming that early HRT initiation did not accelerate subclinical atherosclerosis over the long term 9. This aligns with the "timing hypothesis" endorsed by the 2022 NAMS position statement and the Endocrine Society's 2024 clinical practice guideline, which reaffirmed that systemic HRT is appropriate for symptomatic women who are within 10 years of menopause onset or younger than 60 10.

These long-term data are reassuring for clinicians who prescribe HRT in the early window. They do not, however, support initiating HRT for cardiovascular prevention as a primary indication.

Biomarker-Guided Menopause Diagnosis

Traditional menopause diagnosis relies on 12 consecutive months of amenorrhea. This is impractical for women using hormonal contraception, those with prior hysterectomy, or patients experiencing irregular cycles in the menopausal transition who want clinical answers before a full year passes.

Anti-Mullerian hormone (AMH) is emerging as the most promising predictive biomarker. A pooled analysis of data from the Study of Women's Health Across the Nation (SWAN, N=1,537) found that AMH levels below 0.10 ng/mL predicted final menstrual period within 12 months with 81% accuracy 11. AMH declines predictably throughout the menopausal transition and, unlike FSH, is not significantly affected by oral contraceptive use.

Dr. Nanette Santoro, professor of obstetrics and gynecology at the University of Colorado, noted: "AMH gives us something FSH never could: a forward-looking estimate of when a woman will reach menopause, rather than a backward-looking confirmation that it already happened" 11.

Inhibin B is a complementary marker. When combined with AMH in the SWAN dataset, the two-biomarker panel improved prediction of the final menstrual period within two years to approximately 85% sensitivity 12. Commercial AMH assays (Elecsys, picoAMH) are already validated for fertility assessment, and their adaptation for menopause staging is underway. The 2024 Endocrine Society guidelines acknowledged AMH as a clinically useful adjunct but stopped short of recommending routine measurement outside research settings 10.

Vaginal Microbiome and Genitourinary Syndrome of Menopause

Genitourinary syndrome of menopause (GSM) affects up to 84% of postmenopausal women and includes vaginal dryness, dyspareunia, urinary urgency, and recurrent urinary tract infections 13. While low-dose vaginal estrogen remains first-line treatment, emerging research is examining the vaginal microbiome as both a biomarker and therapeutic target.

Estrogen depletion reduces vaginal Lactobacillus dominance, raises pH above 5.0, and shifts the microbiome toward anaerobic and enteric species. A 2024 observational study (N=320) found that postmenopausal women with Lactobacillus crispatus-dominant vaginal communities had significantly lower GSM symptom scores than those with diverse anaerobic-dominant profiles, even after adjusting for systemic estrogen use 14.

Lactobacillus-based vaginal probiotics are being evaluated in randomized trials as adjuncts to vaginal estrogen. The LADY-2 trial is testing a Lactobacillus crispatus live biotherapeutic (LACTIN-V) plus vaginal estradiol versus estradiol alone for GSM symptom reduction and microbiome restoration. Results are expected in late 2026. Vaginal DHEA (prasterone 6.5 mg intravaginal insert), already FDA-approved for dyspareunia, works partly through local conversion to estrogen and testosterone, which may support Lactobacillus recolonization indirectly 15.

Tissue-Selective Estrogen Complex: Avoiding Progestogen

The tissue-selective estrogen complex (TSEC) pairs conjugated estrogens (0.45 mg) with bazedoxifene (20 mg), a selective estrogen receptor modulator (SERM) that antagonizes estrogen at the endometrium while preserving its agonist activity on bone and its vasomotor effects. This eliminates the need for a progestogen to protect against endometrial hyperplasia.

The SMART trials (SMART-1 through SMART-5) established the efficacy and safety profile of this combination. In SMART-1 (N=3,397, 2 years), the bazedoxifene/CEE combination maintained endometrial thickness comparable to placebo, with a hyperplasia rate below 1% 16. SMART-2 (N=332) demonstrated significant reductions in hot flash frequency (74% reduction vs. 51% for placebo at week 12) 17. SMART-5 confirmed preservation of bone mineral density at the lumbar spine and total hip over 12 months 18.

The clinical appeal of TSEC is straightforward. Women who experience progestogen-related side effects (bloating, mood changes, breast tenderness) or who have progestogen-intolerant conditions may benefit from a regimen that provides endometrial protection through a SERM instead. The 2022 NAMS position statement included TSEC among recommended options for VMS management in postmenopausal women with an intact uterus 19.

Stellate Ganglion Block for Refractory Hot Flashes

Stellate ganglion block (SGB) is a cervical sympathetic nerve block traditionally used for complex regional pain syndrome. Off-label use for refractory VMS has been reported since the early 2010s, and randomized trial data are now accumulating.

A 2020 sham-controlled trial (N=40) found that a single SGB injection reduced VMS frequency by 48% at 6 months, compared to 20% in the sham group 20. A larger multicenter RCT (N=126) completed enrollment in 2024 and is evaluating bilateral SGB for moderate-to-severe VMS with primary endpoints at 8 and 24 weeks. Preliminary data suggest response rates exceeding 50%, though full peer-reviewed results are pending.

SGB remains investigational for this indication. It requires fluoroscopic or ultrasound guidance by a trained interventionalist, and rare but serious complications include pneumothorax and recurrent laryngeal nerve injury. For women who have failed or cannot tolerate both HRT and neurokinin receptor antagonists, SGB represents a procedural option with a growing evidence base.

What the Updated Guidelines Say

The convergence of new evidence has prompted guideline updates from multiple societies. The 2022 NAMS position statement reaffirmed that the benefit-risk ratio is favorable for symptomatic women initiating HRT before age 60 or within 10 years of menopause 19. The Endocrine Society's 2024 guidelines added fezolinetant as a recommended non-hormonal option for VMS and endorsed AMH as a research-supported biomarker for menopause staging 10. The American College of Obstetricians and Gynecologists (ACOG) published a 2024 practice advisory recognizing NK3R antagonists as appropriate for women with contraindications to estrogen 21.

A consistent theme across these updates: menopause management is no longer a binary choice between estrogen and nothing. The available toolkit now includes systemic HRT (oral, transdermal, or vaginal), TSEC, NK3R antagonists, SSRIs/SNRIs, gabapentinoids, vaginal DHEA, and procedural interventions.

Trials to Watch in 2026 and Beyond

Several ongoing trials will shape menopause treatment over the next three to five years.

The EPIONE trial is a phase III study of elinzanetant for menopause-related sleep disturbance as a primary endpoint rather than VMS, which could expand the approved indication beyond hot flashes. The PACE trial is investigating pulsed oral E4 dosing (5 days on, 2 days off) to determine whether intermittent exposure maintains VMS control with further reduced thrombotic risk. A multi-center consortium in Australia is conducting the first adequately powered RCT of cognitive behavioral therapy for menopause (CBT-Meno, N=400), targeting both VMS and the subjective cognitive complaints often called "brain fog."

In the biomarker space, the EPI-Meno study is profiling DNA methylation patterns across the menopausal transition in 2,000 women to identify an epigenetic clock specific to reproductive aging. Early results suggest a methylation-based predictor may outperform AMH for estimating time to final menstrual period in women over 45 22.

For breast cancer survivors, the CALIBRATE trial is testing fezolinetant specifically in women on adjuvant endocrine therapy (tamoxifen or aromatase inhibitors) with moderate-to-severe VMS, a population excluded from the original SKYLIGHT program.

The clinical trajectory is moving toward individualized menopause care: matching drug mechanism, route, and duration to each woman's risk profile, symptom burden, and biomarker status. Fezolinetant 45 mg daily is now the reference non-hormonal comparator, and any new agent entering this space will need to match or exceed its 60% VMS frequency reduction at 12 weeks to gain clinical traction.